Prognose

Das durchschnittliche Kursziel der Analysten beträgt +4,39€(+527,14%). Der Median liegt bei +4,39€(+527,14%).

Kaufen	11
Halten	1
Verkaufen	0

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	3 / 18
Levermann-Strategie	-5 / 13

News

Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials
Immunic Inc (NASDAQ:IMUX) has announced the completion of enrollment for both phase 3 ENSURE trials of its lead asset, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS). The ENSURE program includes two identical, multicenter, randomized, double-blind phase 3 trials, ENSURE-1 and ENSURE-2, designed to assess the efficacy, safety, and tolerability of vidofludimus calcium compared to placebo in patients with RMS.» Mehr auf proactiveinvestors.com
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Further Supports the Recently Released Positive Top-Line Results and Further Underlines Vidofludimus Calcium's Neuroprotective Potential – – New CALLIPER Data Regarding Time to 24-Week Confirmed Disability Worsening Shows Substantial and Medically Relevant Reductions for Vidofludimus Calcium Over Placebo in the Overall Study Population and Major Disease Subtypes – NEW YORK , June 5, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced the completion of enrollment for both phase 3 ENSURE trials of lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with relapsing multiple sclerosis and additional phase 2 CALLIPER trial data in patients with progressive multiple sclerosis underlining the recently released positive top-line results. Enrollment Completed for Both Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis (RMS) The ENSURE program comprises two identical multicenter, randomized, double-blind phase 3 trials designed to evaluate the efficacy, safety and tolerability of vidofludimus calcium versus placebo in RMS patients.» Mehr auf prnewswire.com
Immunic raises $65M in public offering to fund clinical trials
Immunic Inc (NASDAQ:IMUX), a biotechnology firm focused on developing oral therapies for chronic inflammatory and autoimmune diseases, on Tuesday closed a previously announced underwritten public offering, raising approximately $65 million in initial proceeds. The offering consisted of pre-funded warrants, Series A warrants, and Series B warrants to purchase shares of common stock or additional pre-funded warrants.» Mehr auf proactiveinvestors.com

Unternehmenszahlen

Im letzten Quartal hatte Immunic einen Umsatz von 0,00€ und ein Nettoeinkommen von −23,55 Mio€

(EUR)	März 2025	YOY
Umsatz	0,00	-
Bruttoeinkommen	0,00	100,00%
Nettoeinkommen	−23,55 Mio	14,10%
EBITDA	−24,80 Mio	12,18%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+64,31 Mio€
Anzahl Aktien	95,82 Mio
52 Wochen-Hoch/Tief	+1,85€ - +0,49€
Dividenden	Nein
Beta	1,49
KGV (PE Ratio)	−0,80
KGWV (PEG Ratio)	−0,16
KBV (PB Ratio)	−14,66
KUV (PS Ratio)	0,00

Unternehmensprofil

Immunic, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt eine Pipeline selektiver oraler immunologischer Therapien zur Behandlung chronischer Entzündungs- und Autoimmunerkrankungen. Sein führendes Entwicklungsprogramm ist IMU-838, das sich in der klinischen Phase 2 zur Behandlung von schubförmig remittierender Multipler Sklerose, entzündlichen Darmerkrankungen und anderen chronischen Entzündungs- und Autoimmunerkrankungen sowie zur Behandlung von Coronaviruserkrankungen befindet. Das Unternehmen entwickelt außerdem IMU-935, einen inversen Agonisten von ROR?t, und IMU-856 zur Wiederherstellung der Darmbarrierefunktion bei Patienten, die an Krankheiten wie entzündlichen Darmerkrankungen, Reizdarmsyndrom mit Durchfall, durch Immun-Checkpoint-Inhibitoren ausgelöster Kolitis und anderen Erkrankungen der Darmbarrierefunktion leiden. Der Hauptsitz von Immunic, Inc. befindet sich in New York, New York.